Lanyu Mi

Lanyu Mi

Auto-generated profile, based on publicly available information

Lanyu Mi

Department of Urology, Mayo Clinic, Phoenix, AZ

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 February 2019 in American Journal of Transplantation
Verified
Journal Article
Open access
PDF file
KAKara Asbury
Kara Asbury
JBJanis Blair
Janis Blair
JAJessica August
Jessica August
Norman L BeattyNorman L Beatty
Norman L Beatty
LMLanyu Mi
Lanyu Mi
TZTirdad T Zangeneh
Tirdad T Zangeneh
Solid organ transplant recipients who contract coccidioidomycosis are at risk for complicated, protracted, disseminated, and severe disease. To date, no studies have described outcomes for patients who develop coccidioidomycosis only after the first posttransplant year. This study was a joint project of Mayo Clinic Hospital, Phoenix, Arizona, and the University of Arizona/Banner University Medical Center, Tucson, Arizona. We retrospectively reviewed electronic health records for patients with a history of solid organ transplant between January 1, 1998, and October 11, 2014, who developed coccidioidomycosis after the first transplant year. We identified 91 patients. Of those, 37/91 (40.7%) had pulmonary coccidioidomycosis (29/37 [78.4%] were symptomatic); and 5/91 (5.5%) had extrapulmonary disease (all were symptomatic). One patient (1.1%) died. Coccidioidomycosis was evident in 2/91 (2.2%) patients within 3 months of antirejection treatment. Many of the patients (51/91 [56.0%]) had asymptomatic coccidioidomycosis, 27 (27.9%) of whom were followed up closely but did not receive antifungal medication and had no sequelae. Although solid organ recipients taking low‐level immunosuppression after the first posttransplant year appeared to have less symptomatic, disseminated, or fatal coccidioidal infection than historical cohorts, this remains an important infection with morbidity and mortality even after the first post‐transplant year.

16 April 2019 in Western Journal of Emergency Medicine
Verified
Journal Article
Open access
PDF file
NHNicole Rose Hodgson
Nicole Rose Hodgson
KPKarl A. Poterack
Karl A. Poterack
LMLanyu Mi
Lanyu Mi
STStephen Traub
Stephen Traub
Introduction: We sought to determine the association of abnormal vital signs with emergency department (ED) process outcomes in both discharged and admitted patients.Methods: We performed a retrospective review of five years of operational data at a single site. We identified all visits for patients 18 and older who were discharged home without ancillary services, and separately identified all visits for patients admitted to a floor (ward) bed. We assessed two process outcomes for discharged visits (returns to the ED within 72 hours and returns to the ED within 72 hours resulting in admission) and two process outcomes for admitted patients (transfer to a higher level of care [intermediate care or intensive care] within either six hours or 24 hours of arrival to floor). Last-recorded ED vital signs were obtained for all patients. We report rates of abnormal vital signs in each group, as well as the relative risk of meeting a process outcome for each individual vital sign abnormality.Results: Patients with tachycardia, tachypnea, or fever more commonly experienced all measured process outcomes compared to patients without these abnormal vitals; admitted hypotensive patients more frequently required transfer to a higher level of care within 24 hours.Conclusion: In a single facility, patients with abnormal last-recorded ED vital signs experienced more undesirable process outcomes than patients with normal vitals. Vital sign abnormalities may serve as a useful signal in outcome forecasting.

1 January 2024 in Journal of Endourology
Verified
Journal Article
Closed access
DHDaniel J. Heidenberg
Daniel J. Heidenberg
JNJennifer Nauheim
Jennifer Nauheim
CGCampbell M Grant
Campbell M Grant
LMLanyu Mi
Lanyu Mi
CWCharles Van Der Walt
Charles Van Der Walt
PMPatrick Walid Mufarrij
Patrick Walid Mufarrij
Objectives: To determine whether urinary symptoms are significantly improved with a shorter duration of stent placement without an increase in complications. Methods: A total of 100 patients were prospectively randomized to two groups, either a 3 day (N=59, Group 1) or 7 day (N=41, Group 2) stent placement group depending on date of surgery. Patients submitted Ureteral Stent Symptom Questionnaires (USSQ) both while stents were in situ and 2-3 days after removal. Results: Group 2 reported greater urinary symptoms (p<0.001) and pain (p<0.001) with stents in situ compared to Group 1. Urinary symptoms (p< 0.001), pain (p= 0.003) and general health (p=0.02) were more severe in Group 2 after stent removal as well. The analysis also revealed that urinary symptoms, pain, and general health improved after stent removal compared to stent in situ (p<0.001). There were no significant differences in work-related functioning between two groups . There was one complication in Group 1 requiring bilateral stent replacement. There were no significant differences in emergency department visits, unplanned clinic visits or hospitalizations between Groups 1 and 2. Conclusions: Patients with stent removal at 3-day group had better reported urinary, pain and general health score compared to 7-day group. Patients after stent removal had improved urinary symptoms, pain symptom and general health compared to ureteral stent in situ. There was no statistically significant difference in complications between the groups.

1 September 2022 in Journal of Opioid Management
Verified
Journal Article
Closed access
PDF file
RDRitchie Delara
Ritchie Delara
MIMohammad Islam
Mohammad Islam
BTBs Nalani Thomas
Bs Nalani Thomas
LMLanyu Mi
Lanyu Mi
ELElisabeth Lim
Elisabeth Lim
JYJohnny Yi
Johnny Yi
Objective: To determine the impact of shared decision-making in postsurgical opioid prescribing in women who underwent minimally invasive (MIS) hysterectomy.Design: A randomized controlled trial.Setting: A single, tertiary care, academic center.Patients and participants: From January 2019 through April 2020, 73 women aged 18 years and older who had a planned MIS hysterectomy with the Department of Gynecology were enrolled into the study (36 in the standard arm and 37 in the patient-directed arm).Interventions: Participants were assigned either to the standard arm (30 tablets) or patient-directed arm (0–30 tablets) of oxycodone 5 mg.Main outcome measures: The primary outcome was the percentage of excess opioid tablets, calculated by the number of unused tablets divided by the number of tablets prescribed. Secondary outcomes included total opioid tablets used, frequency of obtaining additional opioid tablets after discharge, frequency of unscheduled post-operative visits, and patient satisfaction with number of opioid tablets prescribed.Results: Age, race, and body mass index did not differ between groups. Hysterectomies were performed via laparoscopy (16.9 percent), robotic-assisted laparoscopy (38.5 percent), and vaginal routes (44.6 percent). The median (IQR) number of oxycodone prescribed in the patient-directed arm was 15.0 (12.0 and 24.0) tablets. The standard arm had a greater percentage of excess oxycodone tablets 73.6 percent (0.03) than the patient-directed arm 56.3 percent (0.03, p < .01). However, there was no difference in the total number of oxycodone used by patients in the standard (mean 7.9 [0.5] tablets) and patient-directed arms (mean 8.4 [0.5] tablets, p = .50). The mean number of oxycodone used for the entire cohort was 8.1 (0.4) tablets.Conclusions: Shared decision-making significantly decreased the percent of excess oxycodone tablets but did not decrease the total number of oxycodone tablets used in patients undergoing MIS hysterectomy. Patients used about 22 tablets less than the standard 30 tablets prescribed.

17 April 2023 in Antimicrobial Stewardship & Healthcare Epidemiology
Verified
Journal Article
Open access
PDF file
LCLynn Chan
Lynn Chan
SGSimran Gupta
Simran Gupta
ASAlicia J. Sacco
Alicia J. Sacco
SKSabirah N. Kasule
Sabirah N. Kasule
HCHally Chaffin
Hally Chaffin
MSMaria Teresa Seville
Maria Teresa Seville
Objective: To evaluate the rate of coinfections and secondary infections seen in hospitalized patients with COVID-19 and antimicrobial prescribing patterns. Methods: This single-center, retrospective study included all patients aged ≥18 years admitted with COVID-19 for at least 24 hours to a 280-bed, academic, tertiary-care hospital between March 1, 2020, and August 31, 2020. Coinfections, secondary infections, and antimicrobials prescribed for these patients were collected. Results: In total, 331 patients with a confirmed diagnosis of COVID-19 were evaluated. No additional cases were identified in 281 (84.9%) patients, whereas 50 (15.1%) had at least 1 infection. In total, of 50 patients (15.1%) who were diagnosed with coinfection or secondary infection had bacteremia, pneumonia, and/or urinary tract infections. Patients who had positive cultures, who were admitted to the ICU, who required supplemental oxygen, or who were transferred from another hospital for higher level of care were more likely to have infections. The most commonly used antimicrobials were azithromycin (75.2%) and ceftriaxone (64.9%). Antimicrobials were prescribed appropriately for 55% of patients. Conclusions: Coinfection and secondary infections are common in patients who are critically ill with COVID-19 at hospital admission. Clinicians should consider starting antimicrobial therapy in critically ill patients while limiting antimicrobial use in patients who are not critically ill.

11 September 2023 in Emergency Medicine International
Verified
Journal Article
Open access
PDF file
JSJohnathan Michael Sheele
Johnathan Michael Sheele
LMLanyu Mi
Lanyu Mi
JMJessica Monas
Jessica Monas
MMMichael Mohseni
Michael Mohseni
Introduction. Urinary tract infections (UTIs) and sexually transmitted infections (STIs) can have overlapping signs, symptoms, and findings on urinalysis. Our objective was to determine if patient or provider demographics are associated with differences in the diagnosis and management of UTIs and STIs in the emergency department (ED). Methods. We analyzed 38,062 ED patient encounters from a single healthcare system between April 18, 2014, and March 7, 2017. All encounters were women 18years of age and not admitted to the hospital. We performed logistic regression using patient and provider demographics, laboratory testing results, ED triage data, and ED diagnoses. Results. The patients age, race, and marital status were not associated with having an ED UTI diagnosis with a urine culture 10,000 colony forming units (CFUs)/mL (vs. <10,000CFUs/mL). Patient race and the sex of the ED provider were not associated with differences in empiric antibiotic treatment for gonorrhea and chlamydia during the ED encounter. Patients race and the sex of the ED provider were also not associated with discordance between empiric antibiotic therapy given in the ED and the results of gonorrhea and chlamydia tests that resulted following the ED encounter. Conclusion. In our multivariate analyses, we did not observe that the patients race resulted in significant differences in the diagnosis of UTIs with bacteriuria 10,000CFU/mL or differences in the empiric treatment of gonorrhea and chlamydia infections among those tested for the infection in the ED. The patients age and marital status, but not the providers sex, were significantly associated with differences in the management of gonorrhea and chlamydia.